NCT04963439View on ClinicalTrials.gov

A Study of Two Macitentan Pediatric Formulations in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 8, 2021

Primary Completion Date

September 12, 2021

Study Completion Date

October 5, 2021

Conditions
Healthy
Interventions
DRUG

Macitentan

Macitentan dispersible tablets will be administered orally as per assigned treatment sequence.

Trial Locations (1)

2170

Clinical Pharmacology Unit, Merksem

Sponsors

Lead Sponsor

Actelion
All Listed Sponsors
lead

Actelion

INDUSTRY

NCT04963439 - A Study of Two Macitentan Pediatric Formulations in Healthy Adult Participants | Biotech Hunter | Biotech Hunter